These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26202948)

  • 21. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
    Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
    Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
    Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
    Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
    Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
    Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
    Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression.
    Ahmed AA; Robinson T; Palande M; Escara-Wilke J; Dai J; Keller ET
    J Cell Biochem; 2019 Oct; 120(10):16946-16955. PubMed ID: 31099068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.
    Zhang C; Yan Z; Painter CL; Zhang Q; Chen E; Arango ME; Kuszpit K; Zasadny K; Hallin M; Hallin J; Wong A; Buckman D; Sun G; Qiu M; Anderes K; Christensen JG
    Clin Cancer Res; 2009 Jul; 15(14):4630-40. PubMed ID: 19584159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
    Lin JZ; Hameed I; Xu Z; Yu Y; Ren ZY; Zhu JG
    Oncol Rep; 2018 Oct; 40(4):2242-2250. PubMed ID: 30066906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.
    Timme CR; Gruidl M; Yeatman TJ
    Apoptosis; 2013 Oct; 18(10):1163-74. PubMed ID: 23887890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
    Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.
    Arcaroli JJ; Quackenbush KS; Purkey A; Powell RW; Pitts TM; Bagby S; Tan AC; Cross B; McPhillips K; Song EK; Tai WM; Winn RA; Bikkavilli K; Vanscoyk M; Eckhardt SG; Messersmith WA
    Br J Cancer; 2013 Aug; 109(3):667-75. PubMed ID: 23868008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
    Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
    Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.
    Zheng Y; Wang Z; Ding X; Dong Y; Zhang W; Zhang W; Zhong Y; Gu W; Wu Y; Song X
    Cell Prolif; 2018 Jun; 51(3):e12424. PubMed ID: 29232766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.
    Dirican A; Atmaca H; Bozkurt E; Erten C; Karaca B; Uslu R
    Clin Transl Oncol; 2015 Feb; 17(2):145-51. PubMed ID: 25060568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer.
    Banerjee S; Hussain M; Wang Z; Saliganan A; Che M; Bonfil D; Cher M; Sarkar FH
    Cancer Res; 2007 Apr; 67(8):3818-26. PubMed ID: 17440096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB.
    Lee SY; Cho JS; Yuk DY; Moon DC; Jung JK; Yoo HS; Lee YM; Han SB; Oh KW; Hong JT
    J Pharmacol Sci; 2009 Oct; 111(2):124-36. PubMed ID: 19834284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
    Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
    Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.